Intrapulmonary metastasis of non–small cell lung cancer: A prognostic assessment  by Okumura, Takehiro et al.
24 The Journal of Thoracic and Cardiovascular Surgery • July 2001
General Thoracic Surgery Okumura et al
ED
ITO
RIA
L
G
TS
G
TS
A
CD
ET
CSP
TX
Objective: According to the revised TNM classification in 1997, intrapulmonary
metastasis within the same lobe of the primary tumor is designated as T4 and intra-
pulmonary metastasis in a different lobe is M1. However, their prognostic implica-
tions remain unclear. To assess their prognoses, we retrospectively analyzed the
postoperative survival of patients with and without intrapulmonary metastasis.
Methods:  From January 1982 to December 1996, 2340 patients with non–small cell
lung cancer underwent surgical resection. The survival of patients having complete
resection (n = 1534) was analyzed according to their intrapulmonary metastasis sta-
tus: patients without intrapulmonary metastasis (n = 1393), those with metastasis in
the same lobe (n = 105), and those with metastasis in a different lobe (n = 18). For
comparison, patients with T4 disease without intrapulmonary metastasis in the
same lobe (n = 54) and those with M1 disease without metastasis in a different lobe
(distant M1, n = 18) were also analyzed.
Results:  The overall 5-year survivals were as follows: no intrapulmonary metasta-
sis, 60%; stage T4 disease with no intrapulmonary metastasis, 34%; pulmonary
metastasis in the same lobe, 34%; pulmonary metastasis in a different lobe, 11%;
and distant M1, 6%. The differences in survival between patients with no pul-
monary metastasis and those with metastasis in the same lobe (P < .001, log-rank
test) and between patients with metastasis in the same lobe and those with distant
M1 (P < .001) were significant. In contrast, there was no significant difference
between patients with metastasis in the same lobe and those with T4 disease and no
intrapulmonary metastasis or between patients with metastasis to a different lobe
and those with distant M1.
Conclusions:  Prognostically, intrapulmonary metastasis within the same lobe of the
primary tumor was comparable with T4 and that in a different lobe was comparable
with M1. In terms of postoperative prognosis, the revised TNM classification for
intrapulmonary metastasis seems to be appropriate. 
In the TNM staging system revised in 1987 for lung cancer,1 intrapulmonarymetastasis (PM) was designated as distant metastasis (M1). In contrast, inthe most recent revision of the TNM staging system in 1997,2 PM withinthe same lobe of the primary tumor (PMs) was designated as T4 and PM ina different lobe (PMd) as M1. The rationale for this change is based on astudy by Deslauriers and associates3 that found a favorable prognosis for
patients with PM compared with those with distant metastasis excluding the lung
(distant M1). They stated that local spread could be a possible metastatic mecha-
nism of PM.
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Urschel and coworkers4 claimed that the actual postoper-
ative 5-year survival of patients with PM was 20% on the
basis of a review of 11 reports, which is much higher than
would be expected on the basis of clinical T4 descriptors.
However, it may be questionable to conclude that the pres-
ent TNM classification is inappropriate with comparison of
the survival of PM patients who underwent resection and
clinical T4 descriptors. No previous report has compared
PMs cases with T4 cases with regard to their operative out-
come, even including cases with malignant pleural effusion
and dissemination in the T4 population. The prognostic
implications of PM in lung cancer remain unclear.
We retrospectively analyzed the postoperative prognosis
of patients who had non–small cell lung cancer (NSCLC)
without PM (PM0), with PM, or with distant M1. Moreover,
the postoperative prognosis of patients whose tumors were
designated as T4 for some reason other than PM was also
analyzed. To evaluate the prognostic implications of PM, we
compared these prognoses.
Patients and Methods
Patients
From January 1982 to December 1996, 2340 patients with NSCLC
underwent surgical resection at National Cancer Center Hospital,
Tokyo, Japan. Of these 2340 patients, 200 (9%) had pathological-
ly proven PM on the basis of a postoperative pathologic study. PM
was defined as a parenchymatous satellite lesion that was histo-
logically identical to the main tumor and lacked microscopic fea-
tures suggesting a primary tumor. PM was discriminated from syn-
chronous multiple primary lung cancers on the basis of the criteria
established by Martini and Melamed.5 However, cases without
lymph node involvement were included in the PM population.
Three cases in which such discrimination was difficult were
excluded from this study. Of these 200 patients, 152 had PMs, and
48 had PMd. Complete resection was performed for 1393 patients
with PM0, 105 with PMs, 18 with PMd, and 18 with distant M1.
There were no patients with distant M1 among the PM0, PMs, and
PMd populations. Complete resection was defined as segmentec-
tomy or greater resection of the primary lesion with microscopi-
cally negative surgical margins. However, the patients designated
as T4 for malignant effusion or pleural dissemination were includ-
ed if the primary lesions were resected. Basically, it required medi-
astinal lymph node dissection but permitted a less extensive dis-
section if there was no macroscopically metastatic node after
lymphadenectomy.
Figure 1. Overall survival curves of patients with PM0, PM0T4,
PMs, PMd, and distant M1. The differences in survival between
patients with PMs and with PM0 and between PMs and distant
M1 are significant (P < .001, respectively). The difference in sur-
vival between patients with PMs and with PM0T4 is not signifi-
cant (P = .823).
Figure 2. Survival curves of patients with PMs according to the
provisional pathologic T status defined by excluding PM. There
was no significant difference in survival.
Figure 3. Survival curves of patients with PMs according to the
pathologic nodal status. There was no significant difference in
survival.
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General Characteristics of the Patients
Table 1 shows the general characteristics of each population. PMs
was detected preoperatively in 10 of 105 patients, and PMd was
detected preoperatively in 7 of 18. Sixteen patients had ipsilateral
PMd and 2 had contralateral PMd. Although all contralateral lesions
were resected partially, 5 patients had ipsilateral PMd lesions that
were resected partially, 4 had ipsilateral PMd lesions resected togeth-
er with the primary tumor by bilobectomy, and 7 had such lesions
resected with the primary tumor by pneumonectomy (Table 2). We
defined distant M1 as distant metastasis excluding the lung that was
detected before or within 1 month after complete resection of the pri-
mary lesion and required treatment for the metastatic lesion. Sites of
metastasis and their treatment are shown in Table 3. Among the
patients with PM0, 54 patients were designated as T4 (PM0T4).
These included patients with malignant effusion or pleural dissemi-
nation if the primary lesions were resected (Table 4).
Analysis and Statistics
First, we analyzed the overall postoperative survival of patients
with PM0, PM0T4, PMs, PMd, and distant M1. Second, we ana-
lyzed the survival of patients with PMs according to the provision-
al pathologic T status defined by excluding PM. Similarly, the sur-
vival of patients with PMs was analyzed according to the
pathologic nodal status. Survival was estimated by the Kaplan-
Meier method6 with the date of pulmonary resection as the starting
date. The log-rank test was used to determine the statistical signif-
icance of differences in survival.
TABLE 1.  General characteristics of patients with PM0, PMs, PMd, and distant M1
No. of patients
PM0 PMs PMd Distant M1
Age (y)
Mean ± SD 62 ± 10 62 ± 12 63 ± 14 59 ± 10
Range 26-88 33-82 18-76 34-78
Sex (male/female) 1008/385 73/32 12/6 16/2
Type of operation
Segmentectomy 18 1 1 0
Lobectomy 1194 82 10 14
Pneumonectomy 181 22 7 4
Level of lymph node dissection
Less than hilar 86 5 2 5
Hilar 203 15 3 2
Mediastinal or more 1104 85 13 11
Histology
Adenocarcinoma 829 67 13 11
Squamous cell carcinoma 415 25 5 4
Adenosquamous carcinoma 27 5 0 2
Large cell carcinoma 76 6 0 1
Carcinoid tumors 22 0 0 0
Others 24 2 0 0
Pathologic*
T1 581 29 5 3
T2 574 60 7 11
T3 184 13 6 3
T4 54 3 0 1
Pathologic
N0 822 32 8 7
N1 265 22 5 5
N2 282 49 5 6
N3 24 2 0 0
Total 1393 105 18 18
*Provisional T status defined by excluding PM.
TABLE 2.  Characteristics of patients with PMd
No. of patients
Ipsilateral Contralateral 
Operation PMd PMd
Segmentectomy + partial resection of PMd 1
Single lobectomy + partial resection of PMd 4 2
Bilobectomy 4
Pneumonectomy 7
Total 16 2
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Results
The overall follow-up ranged from 0 to 179 months, with a
median of 47 months. Complete follow-up for 5 years was
obtained for 1112 patients with PM0 (45 patients with
PM0T4), 90 patients with PMs, and 18 patients each with
PMd and distant M1.
Overall Survival
The 5-year survivals of the patients with PM0, PM0T4,
PMs, PMd, and distant M1 were 60%, 34%, 34%, 11%, and
6%, respectively (Figure 1). The differences in survival
between PM0 and PMs (P < .001) and between PMs and
distant M1 (P < .001) were significant. In contrast, the sur-
vival curves for patients with PM0T4 and with PMs nearly
overlapped each other, and the difference in survival
between them was not statistically significant (P = .823).
Similarly, the difference in survival between patients with
PMd and with distant M1 (P = .113) was not significant, as
were those between PMs and PMd (P = .058) and between
PM0T4 and PMd (P = .135). Significant differences in sur-
vival were observed between PM0 and PM0T4, PM0 and
PMd, PM0 and distant M1 (P < .001, respectively) and
PM0T4 and distant M1 (P = .002).
Survival of Patients with PMs According to the
Provisional Pathologic T Status
Among the PMs population, T4 cases showed vital organ
invasion but no malignant pleural effusion or pleural dis-
semination. The 5-year survivals of the PMs cases with
T1, T2, and T3 tumors were 38%, 32%, and 23%, respec-
tively (Figure 2), whereas the 5-year survival with T4
could not be calculated because there was no patient at
risk at 5 years. There was no significant difference in sur-
vival, although the T4 population was too small for a
comparison (T1 vs T2, P = .269; T1 vs T3, P = .116; T1
vs T4, P = .144; T2 vs T3, P = .464; T2 vs T4, P = .182;
T3 vs T4, P = .784).
Survival of Patients with PMs According to the
Pathologic Nodal Status
Two N3 patients were excluded from this analysis because
they were too small to analyze. The 5-year survivals of the
remaining PMs cases with N0, N1, and N2 nodal involve-
ment were 37%, 40%, and 24%, respectively (Figure 3).
There were no significant differences in survival (N0 vs N1,
P = .775; N0 vs N2, P = .188; N1 vs N2, P = .253).
Discussion
It is important to discriminate PM from synchronous multi-
ple primary lung cancers for a discussion of the prognostic
implications of PM. However, in some cases such discrimi-
nation can be difficult. Although new methods7,8 have
recently been applied to this differentiation, they are not
practical at present. Under these conditions it is most prac-
tical to exclude synchronous multiple primary lung cancers
from PM on the basis of the criteria established by Martini
and Melamed5 that have been widely accepted for a diagno-
sis of multiple lung cancer. Consequently, the possibility of
including some cases of synchronous multiple primary lung
cancer in the PM population is inevitable. However, the
incidence of PM in our series was only 9%, which is com-
parable with the 8% observed in the series of Deslauriers
and colleagues.3 Thus, we considered that our PM popula-
tion was worth analyzing.
In our series the 5-year survival of patients with PMs was
34%, which was significantly worse than that of patients
with PM0 and better than that of patients with distant M1.
Yano,9 Okada,10 and their associates also reported that PMs
cases had a worse survival than PM0 cases (37% and 30%
at 5 years, respectively). On the other hand, Shimizu,11
Fukuse,12 and their colleagues reported that PM (PMs +
PMd) cases had a better survival than distant M1 cases (26%
at 5 years). It may be safe to assume that the postoperative
prognosis of patients with PMs is between those of patients
with PM0 and those with distant M1. The problem is where
patients with PMs should be designated in the TNM classi-
fication.
According to the latest TNM classification,2 T4 consists
of 3 populations: (1) a tumor with malignant pleural, peri-
cardial effusion, or pleural dissemination; (2) a tumor that
invades the mediastinum or an adjacent vital organ such as
the heart, great vessels, carina, trachea, esophagus, or verte-
bra; and (3) a tumor with PMs. The 5-year survival for
patients in the former two T4 populations (PM0T4, n = 54;
the first population underwent a resection of the primary
lesion and the second population underwent a complete
TABLE 3.  Characteristics of patients with distant M1
No. of patients
Treatment modality Brain Bone Adrenal gland Subcutaneous tissue Gallbladder
Resection 5 0 3 1 1
Radiation 6 1 0 0 0
Chemotherapy 0 1 0 0 0
Total 11 2 3 1 1
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resection) is 34% in our series. Macchiarini and associates13
reported that the 5-year survival of 14 patients with com-
pletely resected T4 tumor invading adjacent structures was
29%, whereas that of 49 patients with T4 including incom-
plete resections was only 5%. Similarly, Hsu and col-
leagues14 reported that the 5-year survival of 25 patients
with completely resected T4 tumor was 23%. Although the
operative indications of T4 descriptors include a selection
bias, the outcome for patients with PM0T4 in our series is
comparable with their results. In this study the difference in
survival between patients with PMs and PM0T4 was not sta-
tistically significant. The postoperative survival of PMs
cases seems to be comparable with that of T4 cases.
Generally, nodal status is considered to be one of the most
important prognostic factors in NSCLC.15 Shimizu and
coworkers11 reported the survival of PM cases according to
their pathologic nodal and T status. They found that N0 cases
had a better survival than N1 and N2 cases and that T1 cases
had a better survival than T2, T3, and T4 cases. Okada and
associates10 also reported a difference in survival among PM
cases according to the pathologic nodal status. In contrast, no
significant difference in survival was observed among the PMs
cases according to either nodal or T status in our series. This
result suggests that PM may be a strong prognostic factor
equivalent to nodal status for patients with lung cancer.
PMd has been designated as M1 because it was consid-
ered to result from a spread via systemic blood circulation.
The survival of PMd actually was not significantly different
from that of distant organ metastasis in our study. The oper-
ative indications for patients with sublesions in a different
lobe and with distant organ metastasis have a greater selec-
tion bias than those for patients with sublesions within the
same lobe. The actual survivals for patients with PMd and
distant organ metastasis are likely to be considerably worse
than those observed in this study. Consequently, it may be
futile to treat patients with PMd separately from those with
distant organ metastasis. The difference in survival between
patients with PMs and those with PMd was not statistically
significant. Fukuse and coworkers12 reported similar results.
The small number of patients with PMd in this study may
have caused this result.
The present results suggest that the postoperative prog-
nosis of patients with PMs and those with PMd are compa-
rable with those in patients with T4 and with M1, respec-
tively. Although our data concern comparisons of
postoperative prognoses alone, they may support the revised
TNM classification for lung cancer in terms of postoperative
prognosis. Furthermore, PMs may be a poor prognostic fac-
tor that is equivalent to nodal status. Because there is cur-
rently no method for making a definite diagnosis of PM, the
operative indications for patients with sublesions should be
considered carefully.
We are grateful to the Pathology Division, National Cancer
Center Research Institute, Tokyo, Japan, for their useful advice.
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TABLE 4.  Characteristics of PM0 patients designated as T4
T4 descriptors No. of patients
Malignant pleural or pericardial effusion 13
Pleural dissemination 14
Invasion to adjacent major organ 33
Heart and great vessels 18
Vertebral body 2
Carina 10
Trachea 2
Esophagus 1
Total 60 (excluding multiple conditions: 54)
